Literature DB >> 9477108

Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases.

B M Wenig1, L D Thompson, C F Adair, B Shmookler, C S Heffess.   

Abstract

BACKGROUND: Thyroid papillary carcinoma of columnar cell type is considered an uncommon histologic subtype of papillary carcinoma characterized by its morphologic features and purportedly aggressive biologic course.
METHODS: Sixteen cases of thyroid papillary carcinoma of columnar cell type were identified from the Endocrine Tumor Registry at the Armed Forces Institute of Pathology and the Washington Hospital Center. Clinical records and follow-up were available in all cases. Paraffin blocks were available for histochemical and immunohistochemical studies in 15 of the 16 cases.
RESULTS: Of the 16 cases reported, 13 patients were female and 3 were male. The ages ranged from 16-76 years (average, 47 years; median, 40 years). An asymptomatic neck mass was the most common clinical presenting symptom. Macroscopically, the tumors varied from circumscribed or encapsulated to infiltrative, ranging in size from 1.5-6.5 cm. Histologically, the tumors had diverse growth patterns, including papillary, solid, microfollicular, and cribriform. A common pattern was the presence of markedly elongated follicles arranged in parallel cords. Colloid-filled follicles could be found, at least focally, in all cases. The characteristic histologic appearance included the presence of elongated cells showing nuclear stratification. Other features included the presence of vacuolated-appearing cells, spindle-shaped cells, and squamoid nests. Limited areas in the tumors showed morphologic features typical of thyroid papillary carcinoma. In 14 of the cases, the tumor was encapsulated, showed limited invasive growth, or was a microscopic tumor. In two of the cases, there was extrathyroidal invasion. Immunohistochemical studies showed consistent reactivity with cytokeratin and vimentin; varied reactivity with thyroglobulin, epithelial membrane antigen, carcinoembryonic antigen, and LeuM1; and no reactivity with calcitonin or chromogranin. Treatment was by surgical resection; supplemental radioactive iodine therapy was administered in eight patients. Follow-up was available for all patients, 13 of whom (81%) were alive and free of disease or had died of unrelated causes over periods ranging from 2-11 years (average, 5.8 years). All 13 of these patients had tumor confined completely to the thyroid gland. One patient died 4 months after diagnosis secondary to sepsis. Two patients (17%) had aggressive biologic courses. In both patients there was extrathyroidal invasion. One of these patients died of metastatic disease to the lungs 3 years after diagnosis; the other was alive with bilateral pulmonary metastases 9 years after the diagnosis.
CONCLUSIONS: The findings of the current study indicate that thyroid papillary carcinoma of columnar cell type is a distinct morphologic type but not a distinct clinical type of thyroid papillary carcinoma. The biologic behavior of this tumor is predicated on clinical stage, with the presence or absence of extrathyroidal invasion being the single most important parameter. Treatment of patients with these tumors should be based on the clinical stage and not on the morphologic appearance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477108

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Authors:  Tyler Janovitz; Justine A Barletta
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

3.  Images in endocrine pathology: similar, but not the same!

Authors:  Massimo Bongiovanni; Simonetta Piana; Stefano Crippa; Moira Ragazzi; Luca Giovanella
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Columnar cell papillary thyroid carcinoma prognosis: findings from the SEER database using propensity score matching analysis.

Authors:  Shuntao Wang; Yiquan Xiong; Qiuyang Zhao; Haiping Song; Pengfei Yi; Chunping Liu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

6.  High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.

Authors:  I Martínez; A Mantilla; M E Medrano; R Hernández; D M Hernández; M Lazos; H Santiago; B González; A Hidalgo; M Salcedo
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 7.  Where to set the threshold between well differentiated and poorly differentiated follicular carcinomas of the thyroid.

Authors:  Jorge Albores-Saavedra; Kelley Carrick
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

8.  Cytomorphology of columnar cell variant of papillary carcinoma thyroid: A case report and review of the literature.

Authors:  Arijit Sen; Aasma Nalwa; Sandeep R Mathur; Deepali Jain; Venkateswaran K Iyer
Journal:  Cytojournal       Date:  2014-10-21       Impact factor: 2.091

Review 9.  The many faces and mimics of papillary thyroid carcinoma.

Authors:  Jorge Albores-Saavedra; Jianhua Wu
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

10.  Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis.

Authors:  Jianhua Feng; Fei Shen; Wensong Cai; Xiaoxiong Gan; Xingyan Deng; Bo Xu
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.